Updated from 9:00 a.m. EDT

Boston Scientific ( BSX) announced profits that were nearly three times higher than last year and shares rose 5% after the company answered questions about its line of heart-saving stents, which were recalled after causing a number of deaths and serious injuries.

Boston Scientific, which delayed the release of second-quarter results by a week after it widened a recall of its best-selling Taxus stent, announced net income of $313 million, or 36 cents a share, up from the $114 million, or 13 cents a share, it had a year ago. In premarket action, shares of the medical-device maker rose $1.69, or 5%, to $35.28.

But second-quarter results included a charge of $57 million, or 6 cents a share, for the recall and another penny a share in dilution from an acquisition. All told, the recall cut the company's gross margins by $78 million, with a sales reversal of $35 million and a $43 million inventory write-off.

Excluding all items and charges, Boston Scientific said earnings came in at $377 million, or 44 cents a share, which is much better than the year-ago $126 million, or 15 cents a share, but short of the falling Wall Street consensus estimate of 45 cents a share.

Net sales came in at $1.46 billion, up 71% from the $854 million it had a year ago and essentially in line with Wall Street expectations. Excluding currency effects, the company said sales came in at $1.43 million. Still, revenue growth was driven by overall strength in the company's cardiovascular unit, which includes stent sales. Sales from the cardiovascular unit came in at $1.19 billion, up 93% year over year, with Boston Scientific's other lines of business posting double-digit percentage revenue growth from the year-ago quarter.

"We experienced impressive growth across all our businesses and regions, and we are reporting new records in both sales and earnings," said Jim Tobin, president and CEO. "We were especially pleased with the strong conversion rate to drug-eluting stents in the United States, which reached more than 80% by the end of the quarter. This resulted in a significant leveraging of our profitability, and we will be working hard to ensure it continues in the coming quarters."

Despite the recall, the company said that overall worldwide coronary stent sales came in at $652 million, with Taxus sales accounting for $597 million and Express2 stents accounting for $41.6 million.

Boston Scientific said the recall was complete in the U.S. and had gone "better than could be reasonably expected" with the company shipping 40,000 Taxus stents in 48 hours, completely restocking supplies at more than 1,200 accounts. The company said demand for Taxus remained strong, averaging over $6 million a day last week back to 87% of its usual level last Friday, but the recall hurt the company's market share in the drug-soaked stent, at least temporarily.

If you liked this article you might like

Check the Math on Air Fares

Check the Math on Air Fares

US Airways Circles as Pilots Bicker

US Airways Circles as Pilots Bicker

Departure of Delta's Song Unit Boss Stirs Questions

Departure of Delta's Song Unit Boss Stirs Questions

Boeing Boosts Jet Deliveries

Boeing Boosts Jet Deliveries

CEO Gilmartin Will Survive Recall

CEO Gilmartin Will Survive Recall